Brief: 180 Life Sciences Provides Follow-Up Information On Oxford University And The Company’S Successful Dupuytren’S Phase 2B Clinical Trial Results
Dec 6 (Reuters) - 180 Life Sciences Corp ATNF.O :
* 180 LIFE SCIENCES PROVIDES FOLLOW-UP INFORMATION ON OXFORD
UNIVERSITY AND THE COMPANY’S SUCCESSFUL DUPUYTREN’S PHASE 2B
CLINICAL TRIAL RESULTS
* 180 LIFE SCIENCES CORP - BOTH PRIMARY AND SECONDARY
ENDPOINTS
FROM PHASE 2B CLINICAL TRIAL FOR DUPUYTREN'S DISEASE WERE
STATISTICALLY SIGNIFICANT
* 180 LIFE SCIENCES CORP - INITIAL MEETINGS WITH FDA AND
MHRA
CURRENTLY PLANNED FOR H1 2022
Source text for Eikon: ID:nGNX8wW8zc
Further company coverage: ATNF.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Forum Markets
See all newsForum Markets, Inc reports results for the quarter ended June 30 - Earnings Summary
Forum Markets Q2 revenue falls on digital asset exit
Forum Markets, Inc expected to post a loss of 26 cents a share - Earnings Preview
Forum Markets, Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Forum Markets, Inc - To Deploy Capital Into Ai Chip Bridge Loans For Nvidia Gpu Purchases